Gilead’s treatment for the novel coronavirus “could be approved for Covid-19 very soon,” a Piper Sandler analyst said, after what he called “highly encouraging” data in 200 patients for a similar medicine developed by Fujifilm.
- “We now believe the remdesivir clinical trial results are likely to be positive,” analyst
Tyler Van Burensaid of neutral-rated Gilead’s experimental medicine
- “If successful, it could be approved for broad use in the coming months considering it’s safe, the bar for efficacy in the context of the ongoing global pandemic is low,” he said
- NOTE: March 5,
Gilead Analyst Sees Only 50% Chance That...